Marketing-authorisation holder · Canada
Abbvie Corporation
143 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
143 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 143
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTONEL35 mg · Tablet | Risedronate | Canada | Marketed | 2002 |
| ACTONEL150 mg · Tablet | Risedronate | Canada | Marketed | 2008 |
| ACTONEL DR35 mg · Tablet (Delayed-Release) | Risedronate | Canada | Marketed | 2011 |
| ACULAR0.5 % / w/v · Solution | Ketorolac | Canada | Marketed | 1992 |
| ACUVAIL0.45 % / w/v · Solution | Ketorolac | Canada | Marketed | 2012 |
| ALPHAGAN0.2 % / w/v · Solution | Brimonidine | Canada | Marketed | 1997 |
| ALPHAGAN P0.15 % / w/v · Solution | Brimonidine | Canada | Marketed | 2003 |
| BELKYRA10 mg / ml · Solution | Deoxycholic acid | Canada | Marketed | 2016 |
| BOEY1400 unit / vial · Powder For Solution | Botulinum toxin | Canada | Authorised | |
| BOTOX100 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 1992 |
| BOTOX50 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2023 |
| BOTOX200 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2023 |
| BOTOX COSMETIC50 unit / vial · Powder For Solution | Botulinum toxin | Canada | Authorised | |
| BOTOX COSMETIC100 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2001 |
| BYSTOLIC10 mg · Tablet | Nebivolol | Canada | Marketed | 2013 |
| BYSTOLIC5 mg · Tablet | Nebivolol | Canada | Marketed | 2013 |
| BYSTOLIC20 mg · Tablet | Nebivolol | Canada | Marketed | 2013 |
| BYSTOLIC2.5 mg · Tablet | Nebivolol | Canada | Marketed | 2013 |
| COMBIGAN0.2 % / w/v + 0.5 % / w/v · Solution | Brimonidine, Timolol | Canada | Marketed | 2003 |
| CONSTELLA72 mcg · Capsule | Linaclotide | Canada | Marketed | 2018 |
| CONSTELLA290 mcg · Capsule | Linaclotide | Canada | Marketed | 2014 |
| CONSTELLA145 mcg · Capsule | Linaclotide | Canada | Marketed | 2014 |
| DUODOPA5 mg / ml + 20 mg / ml · Gel | Carbidopa, Levodopa | Canada | Marketed | 2008 |
| ELAHERE100 mg / 20 ml · Solution | Mirvetuximab soravtansine | Canada | Marketed | 2026 |
| EPKINLY60 mg / ml · Solution | Epcoritamab | Canada | Marketed | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 143 | 107 | 36 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.